What happened in this Health story?

The FDA told a federal court its safety review of the abortion pill mifepristone will stretch into 2027, disappointing anti-abortion groups who had pressed the Trump administration to quickly restrict the drug.

What is a key fact in this story? (1)

**FDA** said in a court filing Wednesday that its safety study of mifepristone is expected to wrap by mid-December, with a formal report due "no later than March 2027," after which the agency will decide whether to impose new restrictions.

What is a key fact in this story? (2)

**Health Secretary Robert F. Kennedy Jr.** ordered the reevaluation, and the court-ordered update was filed in a case brought by Louisiana alleging that mail-delivery of the pill undermines the state's abortion ban.

📎 SkimNews has covered FDA 81+ times · see the file →

FDA says its safety review of abortion pill will continue into next year — SkimNews

By STAT News · Summarized & edited by Kapil Samant · 2026-10-08

Get the Health newsletter

Daily health & science — research, biotech, public health, the studies worth knowing. Free.

FDA said in a court filing Wednesday that its safety study of mifepristone is expected to wrap by mid-December, with a formal report due "no later than March 2027," after which the agency will decide whether to impose new restrictions.
Health Secretary Robert F. Kennedy Jr. ordered the reevaluation, and the court-ordered update was filed in a case brought by Louisiana alleging that mail-delivery of the pill undermines the state's abortion ban.
Gavin Oxley of Americans United for Life condemned the timeline, accusing the Trump administration of lacking "true leadership" and being "on the wrong side of women's health" by not curbing the drug's use sooner.
Mifepristone, first approved in 2000 and repeatedly reaffirmed as safe by the FDA, is used in the two-drug regimen with misoprostol that accounts for the most common form of abortion in the U.S.
A three-judge panel on the 5th U.S. Circuit Court of Appeals questioned the merits of Louisiana's case last month, including the state's legal standing, though the Supreme Court has blocked any changes to the drug until it revisits the case.
Anti-abortion groups have focused their pressure on a 2021 decision allowing online prescriptions and mail delivery, made permanent under President Joe Biden in 2023, which circumvented state abortion bans.

Why it matters: The March 2027 report deadline pushes any decision on new mifepristone restrictions past the 2026 midterms, denying anti-abortion groups and their congressional allies a near-term policy win. With the Supreme Court already blocking changes to the drug until it revisits the case, the FDA's extended timeline keeps the current telehealth abortion framework in place through the next election cycle.